Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease).
Voigtländer
C
C
Department of Dermatology, University of Erlangen-Nürnberg, Erlangen, Germany.
Lüftl
M
M
Schuler
G
G
Hertl
M
M
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001132:Arm; D001943:Breast Neoplasms / Q000601:surgery; D002097:C-Reactive Protein; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D007958:Leukocyte Count; D012872:Skin Diseases, Vesiculobullous / Q000188:drug therapy*; D013909:Thorax; D014409:Tumor Necrosis Factor-alpha
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D000069285:Infliximab